{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-066233","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.248080+00:00","generated_at":"2026-06-11T14:57:46.993293+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Jasper Therapeutics Q2 2023 net loss $16.1M; cash $115.8M; first patient dosed in LR-MDS trial","bullets":["Net loss of $16.1M for Q2 2023 vs $10.4M in Q2 2022; R&D expenses increased to $13.3M from $8.1M.","Cash and cash equivalents $115.8M as of June 30, 2023, up from $38.3M at Dec 31, 2022; runway through 2024.","First patient dosed in Phase 1 trial of briquilimab for lower-risk MDS (LR-MDS) at Moffitt Cancer Center.","Key appointments: Scott Brun to Board, Edwin Tucker as CMO, and others to Scientific Advisory Board and leadership.","Company plans to initiate chronic spontaneous urticaria study in coming months."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-066233","json":"https://secwatch.observer/filing/0001213900-23-066233.json","markdown":"https://secwatch.observer/filing/0001213900-23-066233.md","text":"https://secwatch.observer/filing/0001213900-23-066233.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023066233/0001213900-23-066233-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023066233/ea183229-8k_jasperthera.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T14:57:46.993293+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ab8aefd0b146260d97e688270d39aa9b029be7fc","claim":"Jasper Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net Loss: For the quarter ended June 30, 2023, net loss was $16.1 million compared to net loss of $10.4 million for the.","evidence_excerpt":"On August 11, 2023, Jasper Therapeutics, Inc. issued a press release reporting its financial results for the quarter ended June 30, 2023 and providing a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023066233/0001213900-23-066233-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Net income","value":"Net Loss: For the quarter ended June 30, 2023, net loss was $16.1 million compared to net loss of $10.4 million for the"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}